Reputation – HCPs: Research and Development
Read more about how healthcare professionals see the pharmaceutical sector’s contribution to research and development
HCPs continue to have a positive opinion of the sector’s commitment to R&D
Research and Development (R&D) remains the most important reputational strength for pharmaceutical companies operating in the UK. A majority of HCPs who took part in this research believe that the sector invests significant sums of money into high quality research into ne medicines and uses the latest, cutting-edge technology. Most agree that pharmaceutical companies operating in the UK produce safe, effective medicines that people need.
I trust pharmaceutical companies as they do a lot of research in order to benefit patients GP
Share this chart: https://www.datawrapper.de/_/rOBL5/
Pharmaceutical companies operating the in UK attract positive recognition for their contribution beyond our shores. Eight in ten believe the sector contributes to improving health globally. Almost nine in ten believe the UK sector plays a leading global role in new medicine discovery. Furthermore, almost two in three HCPs in this study believe the sector has more advanced R&D than in other countries. It is clearly a source of local pride.
The UK represents a global leader in pharmaceutical research and demonstrates gold standard rigour and ethical considerations in its trials GP
Share this chart: https://www.datawrapper.de/_/rOBL5/
There is again a high degree of recognition of the contribution the sector makes to the UK. Three in four believe pharmaceutical companies operating in the UK create lots of jobs. Two in three believe it makes a positive contribution to the economy. However, there is less certainty among HCPs this year as to whether the sector makes a positive contribution to societal challenges and issues.
They are well known throughout the world and are at the top of their game GP
Share this chart: https://www.datawrapper.de/_/fUC8w/
Last modified: 17 October 2024
Last reviewed: 17 October 2024